Vera Q1 2023 Earnings Report
Key Takeaways
Vera Therapeutics reported a net loss of $30.1 million, or a net loss per diluted share of $0.80 for the quarter ended March 31, 2023. The company's cash, cash equivalents, and marketable securities totaled $197.2 million as of March 31, 2023.
36-week data from the Phase 2b ORIGIN clinical trial of atacicept in IgAN was selected for presentation as a late breaking clinical trial at ERA Congress 2023.
The company plans to initiate a pivotal Phase 3 clinical trial of atacicept in IgAN during the second quarter of 2023.
Vera Therapeutics has a strong balance sheet expected to fund operations to early 2026.
Positive interim 24-week data from the Phase 2b ORIGIN clinical trial of atacicept in IgAN showed a statistically and clinically significant reduction in mean proteinuria versus placebo.